Poxvirus vaccines for cancer and HIV therapy

Bibliography

• MOSS B: In: Fields' Virology 4th ed., Knipe DM, Howley PM (Eds), Lipincott Williams & Wilkins: Philadelphia (2001):2849–2883.
   Google Scholar
• REDFIELD RR, WRIGHT DC, JAMES WD, JONES TS, BROWN C, BURKE DS: Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl. J. Med. (1987) 316(11):673–676.
   PubMed Web of Science ®Google Scholar
• MEYER H, SUTTER G, MAYR A: Mapping of the deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol (1991) 72(5):1031–1038.
   PubMedGoogle Scholar
• CARROLL MW, MOSS B: Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology (1997) 238(2):198–211.
   PubMed Web of Science ®Google Scholar
• BHARDWAJ N: Processing and presentation of antigens by dendritic cells: implications for vaccines. Trends Ma Med. (2001) 7(9):388–394.
   PubMed Web of Science ®Google Scholar
• BANCHEREAU J, BRIERE F, CAUX C et al.: Immunobiology of dendritic cells. Ann. Rev. Inanunol (2000) 18:767–811.
   PubMed Web of Science ®Google Scholar
• LARSSON M, FONTENEAU J-F, SOMERSAN S et al.: Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells. Ear: J. Immunol (2001) 31:3432–3442.
   PubMed Web of Science ®Google Scholar
• ENGELMAYER J, LARSSON M, LEE A et al.: Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals. J. Virol. (2001) 75:2142–2153.
   PubMed Web of Science ®Google Scholar
• POPE M, GEZELTER S, GALLO N, HOFFMAN L, STEINMAN PM: Low levels of HIV-1 infection in cutaneous dendritic cells promote extensive viral replication upon binding to memory CD4+ T cells. J Exp. Med. (1995) 182 (6): 2045–2056.
   PubMed Web of Science ®Google Scholar
• CAMERON PU, FREUDENTHAL PS, BARKER JM, GEZELTER S, INABA K, STEINMAN RM. Dendritic cells exposed to human immunodeficiency virus type-I transmit a vigorous cytopathic infection to CD4+ T cells. Science (1992) 257(5068):383–387.
   PubMed Web of Science ®Google Scholar
• CHEHIMI J, STARR SE, FRANK I et al.: Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J. Exp. Med. (1994) 179(4):1361–1366.
   PubMed Web of Science ®Google Scholar
• KANTOR J, IRVINE K, ABRAMS S et al: Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. / Natl. Cancer Inst. (1992) 84(14):1084–1091.
   PubMed Web of Science ®Google Scholar
• WILLEY RL, BYRUM R, PIATAK Metal.: Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles. .1 Virol. (2003) 77:1163–1174.
   Google Scholar
• EARL PL, WYATT LS, MONTEFIORI DC et al.: Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology (2002) 294:270–281.
   PubMed Web of Science ®Google Scholar
• BAROUCH DH, SANTRA S, KURODA MJ et al.: Reduction of Simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia Ankara vaccination. Virol. (2001) 75(11):5151–5158.
   Google Scholar
• MCANENY D, RYAN CA, BEAZLEY PM, KAUFMAN HL: Results of a Phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann. Surg. Oncol (1996) 3(5):495–500.
   PubMed Web of Science ®Google Scholar
• HORIG H, LEE DS, CONKRIGHT W et al.: Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 costimulatory molecule. Cancer Immunol Immunothec (2000) 49:504–514.
   Google Scholar
• WEI X, DECKER JM, WANG S et al: Antibody neutralization and escape by HIV-1. Nature (2003) 422(6929):307–312.
   PubMed Web of Science ®Google Scholar
• MOORE JP, PARREN PW, BURTON DR: Genetic subtypes, humoral immunity and human immunodeficiency virus type 1 vaccine development. J. Vim/. (2001) 75(13):5721–5729.
   Web of Science ®Google Scholar
• LAMBERT JS, MCNAMARA J, KATZ SL et al.: Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. National Institutes of Health-sponsored Pediatric AIDS Clinical Trials Group (ACTG 218). Acquir. Immune. Defic. Syndr. Hum. Retrovirol (1998) 19(5):451–461.
   Google Scholar
• ESSAJEE SM, YOGEV R, POLLACK H, GREENHOUS B, KRASINSKI K, BORKOWSKY W: Recombinant glycoprotein vaccines for human immunodeficiency virus-infected children and their effects on viral quasispecies. Clin. Diagn. Lab. Immunol (2002) 9(1):79–82.
   PubMedGoogle Scholar
• MCELRATH MJ, COREY L, GREENBERG PD et al: Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proc. Natl. Acad. Sci. USA (1996) 93(9)3972–3977.
   Google Scholar
• BETTS MR, AMBROZAK DR, DOUEK DC et al.: Analysis of total human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell responses: relationship to viral load in untreated HIV infection. / Virol. (2001) 75(24):11983–11991.
   PubMed Web of Science ®Google Scholar
• KAUL R, ROWLAND-JONES SL, KIMANI J et al.: New Insights into HIV-1 specific cytotoxicT-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol Lett. (2001) 79(1-2):3–13.
   PubMed Web of Science ®Google Scholar
• ADDO MM, ALTFELD M, ROSENBERG ES et al.: The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1 infected individuals. Proc. Natl. Acad. Sci. USA (2001) 98(4):1781–1786.
   PubMed Web of Science ®Google Scholar
• GRUTERS RA, VAN BAALEN CA, OSTERHAUS AD: The advantage of early recognition of HIV-infected cells by cytotoxic lymphocytes. Vaccine (2002) 20(15):2011–2015.
   PubMed Web of Science ®Google Scholar
• VAN BAALEN CA, PONTESILLI O, HUISMAN RC et al.: Human immunodeficiency virus type-1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen. Virol (1997) 78(8):1913–1918.
   PubMedGoogle Scholar
• HEL Z, VENZON D, POUDYAL M et al.: Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat. Med. (2000) 6(10):1140–1146.
   PubMed Web of Science ®Google Scholar
• SETH A, OURMANOV I, SCHMITZ JE et al: Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J Viral. (2000) 74(6):2502–2509.
   PubMed Web of Science ®Google Scholar
• HEL Z, TSAI WP, THORNTON A et al.: Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J. Immunol (2001) 167(12):7180–7191.
   PubMed Web of Science ®Google Scholar
• AMARA RR, VILLINGER F, ALTMAN JD et al: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/ MVA vaccine. Vaccine (2002) 20(15):1949–1955.
   PubMed Web of Science ®Google Scholar
• •Recommended reading.
   Google Scholar
• MASCOLA JR, NABEL GJ: Vaccines for the prevention of HIV-1 disease. Curr. Opin. Immunol (2001) 13(4):489–495.
   PubMed Web of Science ®Google Scholar
• MCMICHAEL AJ, HANKE T: HIV vaccines 1983-2003. Nat. Med. (2003) 9(7):874–880.
   PubMed Web of Science ®Google Scholar
• FLEURY B, JANVIER G, PIALOUX G et al.: Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)- negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with recombinant gp 160.1 Infect. Dis. (1996) 174(4):734–738.
   Google Scholar
• EVANS TG, KEEFER MC, WEINHOLD KJ et al.: A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes alone, or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. Infect. Dis. (1999) 180(2):290–298.
   Google Scholar
• CAO H, KALEEBU P, HOM D et a/.: Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 vaccine study. J. Infect. Dis. (2003) 187(6):887–895.
   Google Scholar
• HANKE T, MCMICHAEL AJ, MWAU M et al.: Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine (2002) 20(15):1995–1998.
   PubMed Web of Science ®Google Scholar
• PARKER SL, TONG T, BOLDEN S, WINGO PA: Cancer statistics. CA Cancer Clin. (1997) 47:5–27.
   PubMed Web of Science ®Google Scholar
• DERMIME S, ARMSTRONG A, HAWKINS RE, STERN PL: Cancer vaccines and immunotherapy. Br. Med. Bull. (2002) 62:149–162.
   PubMed Web of Science ®Google Scholar
• PERALES MA, WOLCHOK JD: Melanoma vaccines. Cancer Invest. (2002) 20:1012–1026.
   PubMed Web of Science ®Google Scholar
• ••Review of melanoma vaccines.
   Google Scholar
• SCHUTZ A, OERTLI D, MARTI WR et al.: Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/ Melan-A antigen. Cancer Gene Ther. (2001) 8:655–661.
   PubMed Web of Science ®Google Scholar
• ADAMS M, BORYSIEWICZ L, FIANDER A et al.: Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine (2001) 19:2549–2556.
   PubMed Web of Science ®Google Scholar
• KAUFMANN AM, STERN PL, RANKIN EM et al.: Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin. Cancer Res. (2002) 8:3676–3685.
   PubMed Web of Science ®Google Scholar
• ••Results showed the vaccination of rVVencoding E6 and E7 is well tolerated and produces HPV-specific CTL response.
   Google Scholar
• ROSALES C, GRAHAM VV, ROSAS GA, MERCHANT H, ROSALES R: A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity. Cancer Immunol Immunother. (2000) 49:347–360.
   PubMed Web of Science ®Google Scholar
• VALDEZ GV, SUTTER G, JOSE MV et al.: Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus. Cancer (2000) 88: 1650-1662.
   Google Scholar
• CORONA GUTIERREZ CM, TINOCO A, LOPEZ CONTRERAS M et al.: Clinical protocol. A Phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus. Hum. Gene Titer. (2002) 13:1127–1140.
   Google Scholar
• •Describes the most recent clinical trial.
   Google Scholar
• BERINSTEIN NL: Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. Clin. Oncol (2002) 20:2197–2207.
   Web of Science ®Google Scholar
• ••Review on previous studies on CEA.
   Google Scholar
• SCHMITZ J, REALI E, HODGE JW et al.: Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res. (2002) 62:5058–5064.
   PubMed Web of Science ®Google Scholar
• ZAREMBA S, BARZAGA E, ZHU M, SOARES N, TSANG KY, SCHLOM J: Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. (1997) Cancer Res. 57(20):4570–4577.
   Google Scholar
• MARSHALL JL, HOYER RJ, TOOMEY MA et al.: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol (2000) 18:3964–3973.
   PubMed Web of Science ®Google Scholar
• ••First Phase I study with prime-booststrategies in patients.
   Google Scholar
• HODGE JW, SCHLOM J, DONOHUE SJ et al.: A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int. J. Cancer (1995) 63:231–237.
   PubMed Web of Science ®Google Scholar
• TERASAWA H, TSANG KY, GULLEY J, ARLEN P, SCHLOM J: Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin. Cancer Res. (2002) 8:41–53.
   PubMed Web of Science ®Google Scholar
• EDER JP, KANTOFF PW, ROPER K et al.: A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. (2000) 6:1632–1638.
   PubMed Web of Science ®Google Scholar
• GULLEY J, CHEN AP, DAHUT W et al.: Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate (2002) 53:109–117.
   PubMed Web of Science ®Google Scholar
• ••Results show the antitumour effects ofrV-PSA in prostate cancer patients.
   Google Scholar
• KAUFMAN HL, WANG W, MANOLA J et al.: Prime/boost vaccination using poxviruses expressing PSA in DO prostate cancer: preliminary results of ECOG 7897, a randomized Phase II clinical trial. Proc. Am. Soc. Clin. Oncol (2002) 21:4a.
   Google Scholar
• SCHOLL SM, BALLOUL JM, LE GOC G et al.: Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. Immunother. (2000) 23:570–580.
   Google Scholar
• •Results show the use of rW on breast cancer patients.
   Google Scholar
• ZALOUDIK J, LI W, JACOB L et al.: Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/C017-1A/ EpCAM/KSA/KS1-4 antigen in mice. Cancer Gene Ther. (2002) 9:382–389.
   PubMed Web of Science ®Google Scholar
• HOLLSTERIN M, SIDRANSKY D, VOGELSTEIN B, HARRIS CC: p53 mutations in human cancers. Science (1991) 253:49–53.
   PubMed Web of Science ®Google Scholar
• ROSENWIRTH B, KUHN EM, HEENEY JL et al.: Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the intravenous route in rhesus macaques. Vaccine (2001) 19(13-14):1661–1670.
   PubMed Web of Science ®Google Scholar
• ODIN L, FAVROT M, POUJOL D et a/.: Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53. Cancer Gene Ther. (2001) 8:87–98.
   Google Scholar
• VAN DER BURG SH, MENON AG, REDEKER A et a/.: Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin. Cancer Res. (2002) 8:1019–1027.
   Google Scholar
• ••Describes the effects of ALVAC-p53 oncolorectal cancer patients in Phase I/II study.
   Google Scholar
• MEKO JB, YIM JH, TSUNG K, NORTON JA: High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res. (1995) 55:4765–4770.
   PubMed Web of Science ®Google Scholar
• MASTRANGELO MJ, MAGUIRE HC, LATTIME EC: Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma. Adv. Exp. Med. Biol. (2000) 465:391–400.
   PubMed Web of Science ®Google Scholar
• QIN H, VALENTINO J, MANNA Set al.:Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression. Mol. Ther. (2001) 4:551–558.
   Google Scholar
• CHEN B, TIMIRYASOVA TM, GRIDLEY DS, ANDRES ML, DUTTA-ROY R, FODOR I: Evaluation of cytokine toxicity induced by vaccinia virus-mediated IL-2 and IL-12 antitumour immunotherapy. Cytokine (2001) 15:305–314.
   PubMed Web of Science ®Google Scholar
• KAUFMAN HL, FLANAGAN K, LEE CS, PERETTA DJ, HORIG H: Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine (2002) 20: 1862-1869.
   Google Scholar
• KASS E, PANICALI DL, MAZZARA G, SCHLOM J, GREINER JW: Granulocyte/ macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res. (2001) 61:206–214.
   PubMed Web of Science ®Google Scholar
• GRIFFITH TS, KAWAKITA M, TIAN J et al.: Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses. J. Natl. Cancer Inst. (2001) 93:998–1007.
   Google Scholar
• YANG AS, MONKEN CE, LATTIME EC: Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen. Cancer Res. (2003) 63(20):6956–6961.
   PubMed Web of Science ®Google Scholar
• CHEN L, ASHE S, BRADY WA et al: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell (1992) 71:1093–1102.
   PubMed Web of Science ®Google Scholar
• TOWNSEND SE, ALLISON JP: Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 259:368–370.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ RH: Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell (1992) 71(7):1065–1068.
   PubMed Web of Science ®Google Scholar
• CARRENO BM, COLLINS M: The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Ann. Rev. Immunol. (2002) 20:29–53.
   PubMed Web of Science ®Google Scholar
• HODGE JW, GROSENBACH DW, PAD AN, GIULIANO M, SABZEVARI H, SCHLOM J: Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. Vaccine (2001) 19:3552–3567.
   PubMed Web of Science ®Google Scholar
• PAD AN, SCHLOM J, HODGE J: Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors. Crit. Rev Oncol. Hematol (2001) 39(1-2):43–57.
   PubMed Web of Science ®Google Scholar
• AARTS WM, SCHLOM J, HODGE JW: Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res. (2002) 62:5770–5777.
   PubMed Web of Science ®Google Scholar
• •Addition of combination of TRICOM and cytokine (GM-CSF and IL-2) in prime-boost strategies generated enhanced T cell responses.
   Google Scholar
• GREINER JW, ZEYTIN H, ANVER MR, SCHLOM J: Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res. (2002) 62(23):6944–6951.
   PubMed Web of Science ®Google Scholar
• GROSENBACH DW, BARRIENTOS JC, SCHLOM J, HODGE J: Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res. (2001) 61(11):4497–4505.
   PubMed Web of Science ®Google Scholar
• KAUFMAN HL, CHEUNG K, HASKALL Z et al.: Intra-lesional rF-B7.1 versus rF-TRICOM vaccine in the treatment of metastatic cancer. Hum. Gene Ther. (2003) 14:803–827.
   Google Scholar
• VON MEHREN M, ARLEN P, GULLEY J et al.: The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. (2001) 7:1181–1191.
   Google Scholar
• •Shows that a dual gene avipox containing CEA and B7.1 gene can generate increased CEA-specific precursors in human.
   Google Scholar
• BAROUCH DH, SANTRA S, SCHMITZ JE et al.: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 290(5491):486–492.
   PubMed Web of Science ®Google Scholar
• BAROUCH DH, SANTRA S, TENNER-RACZ K et al.: Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSE I Immunol. (2002) 168(2):562–568.
   Google Scholar
• SHANKAR P, SCHLOM J, HODGE JW: Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3). Vaccine (2001) 20:744–755.
   Google Scholar
• STITTELAAR KJ, GRUTERS RA, SCHUTTEN M et al.: Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine (2002) 20(23-24):2921–2927.
   PubMed Web of Science ®Google Scholar
• ZEH HJ, BARTLETT DL: Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther. (2002) 9(12):1001–1012.
   PubMed Web of Science ®Google Scholar
• MORSE MA, NAIR SK, BOCZKOWSKI D et al.: The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int. J. Gastrointest. Cancer (2002) 32(1):1–6.
   PubMedGoogle Scholar
• MORSE MA, NAIR SK, MOSCA PJ et al.: Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest. (2003) 21(3):341–349.
   PubMed Web of Science ®Google Scholar
• LU W, WU X, LU Y, GUO W, ANDRIEU JM: Therapeutic dendritic cell vaccine for simian AIDS. Nat. Med. (2003) 9(1)27-32. Websites
   Google Scholar
• http://www.vaxgen.com VaxGen website.
   Google Scholar
• http://www.iavi.org The International AIDS Vaccine Initiative.
   Google Scholar
• http://www.hvtn.org HIV Vaccine Trials Network.
   Google Scholar
• http://www.hptn.org HIV Prevention Trials Network.
   Google Scholar